SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company’s first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. This growth underscores the accelerating adoption of its SSi Mantra surgical robotic system, which is expanding its global footprint and clinical applications.
The company’s gross profit for the second quarter increased 20.0% to $7.1 million, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with an improved gross margin. The revenue surge was driven by a 30.4% increase in SSi Mantra installations, reaching 30 systems during the quarter. The installed base now stands at 224 systems across 12 countries, with a cumulative 12,272 surgeries performed using the platform.
These results highlight a pivotal period for SS Innovations as it prepares for significant regulatory milestones. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open the door to the lucrative U.S. and European markets, potentially transforming the company’s growth trajectory. The company’s telesurgery achievements are also extending the clinical profile of SSi Mantra, demonstrating its capabilities beyond traditional settings and positioning it as a versatile tool for remote surgical procedures.
The strong revenue growth and expanding installation base indicate that SSi Mantra is gaining traction among healthcare providers, who are increasingly recognizing the benefits of robotic-assisted surgery, such as improved precision, reduced patient recovery times, and enhanced surgical outcomes. As the company continues to innovate and secure regulatory clearances, it is well-positioned to capitalize on the growing demand for minimally invasive surgical solutions worldwide.
Investors and industry observers are closely watching SS Innovations’ progress, as the company’s performance reflects broader trends in the surgical robotics market, which is expected to grow substantially in the coming years. With a robust pipeline of installations and strategic regulatory advancements on the horizon, SS Innovations is poised to strengthen its competitive position and deliver long-term value to stakeholders.
